

## SPECIALTY QUANTITY LIMIT PROGRAM

### POMALYST (pomalidomide)

#### I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. If the member's plan allows a quantity limit exception review for the requested medication, coverage of an additional quantity may be provided up to the exception limit with prior authorization. The recommended dosing parameters for the prevention or treatment of multiple myeloma fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

#### II. COVERED QUANTITIES

Medication	FDA-recommended dosing	Standard Limit
Pomalyst (pomalidomide) capsules 1mg	Multiple myeloma: 4 mg per day taken orally on Days 1-21 of repeated 28-day cycles	21 per 21 days
Pomalyst (pomalidomide) capsules 2mg		21 per 21 days
Pomalyst (pomalidomide) capsules 3mg		21 per 28 days
Pomalyst (pomalidomide) capsules 4mg		21 per 28 days

#### III. REFERENCES

1. Pomalyst [package insert]. Summit, NJ: Celgene Corporation; June 2016.